Coherus Oncology (CHRS) Interest & Investment Income (2018)

Coherus Oncology (CHRS) reported Interest & Investment Income of -$1000.0 for Q1 2018.

Coherus Oncology (CHRS) Interest & Investment Income (2018) Analysis & Trends

Coherus Oncology (CHRS) has 1 years of Interest & Investment Income data on file, last reported at -$1000.0 in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 27.66 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 114.80 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -65.80 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 48.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - 19.51 Mn
10 Coherus Oncology 200.42 Mn 33.38 Mn 8.50 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2018 -1,000.00